Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01629745|
Recruitment Status : Completed
First Posted : June 28, 2012
Last Update Posted : May 19, 2016
RATIONALE: Testing for minimal residual disease in blood samples from patients with acute lymphoblastic leukemia may help doctors plan better treatment.
PURPOSE: This research trial studies a genetic test in detecting minimal residual disease in samples from younger patients registered on COG-AALL08B1 trial.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: gene expression analysis Other: flow cytometry Other: laboratory biomarker analysis|
- Assess the feasibility of minimal residual disease (MRD) determination in pediatric B-lineage acute lymphoblastic leukemia (ALL) using deep sequencing of the immunoglobulin heavy chain locus.
OUTLINE: Archived blood and tumor tissue samples are analyzed for MDR using deep sequencing of immunoglobulin heavy chain locus. MDR quantification results are then compared with the flow cytometry reference methods used in COG studies.
|Study Type :||Observational|
|Estimated Enrollment :||99 participants|
|Official Title:||Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus|
|Study Start Date :||June 2012|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||May 2016|
- Sensitivity of deep sequencing of the immunoglobulin heavy chain locus in determining MRD in B-lineage ALL
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01629745
|Principal Investigator:||Brent Wood, MD, PhD||Seattle Cancer Care Alliance|